Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies

New York, NY – July 21, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its…

ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer’s Hallmarks in Preclinical Disease Model

Data Presented at 2014 Alzheimer’s Association International Conference (AAIC) New York, NY – July 14, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, has unveiled promising preclinical…